← Eichor
Condition: Essential Thrombocythemia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Essential Thrombocythemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Phase 1 · 5 location(s) · Prelude Therapeutics · NCT07469891Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative
Phase 1/Phase 2 · 7 location(s) · Jubilant Therapeutics Inc. · NCT07612280A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05714072A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
Phase N/A · 24 location(s) · FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · NCT07203768Research Platform Myelofibrosis and Anemia
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06976918A Study of GLB-001 in Patients With Myeloid Malignancies
Phase 1 · 14 location(s) · Hangzhou GluBio Pharmaceutical Co., Ltd. · NCT06378437Therapeutic RSK1 Targeting in Myelofibrosis
Phase 1 · 1 location(s) · Washington University School of Medicine · NCT07379125Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis
Phase 2 · 1 location(s) · The University of Hong Kong · NCT06770842Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
NA · 3 location(s) · University Hospital, Angers · NCT06361641Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm
Phase N/A · 1 location(s) · Université Catholique de Louvain · NCT07590986Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
Phase 2 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT06541249Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia
NA · 2 location(s) · West China Second University Hospital · NCT06881056A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
Phase N/A · 3 location(s) · Bristol-Myers Squibb · NCT06073847National Longitudinal Cohort of Hematological Diseases
Phase N/A · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT04645199A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Phase 3 · 21 location(s) · Merck Sharp & Dohme LLC · NCT06351631An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
Phase 1/Phase 2 · 2 location(s) · University of California, Irvine · NCT05123365Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Phase 1 · 1 location(s) · Fox Chase Cancer Center · NCT06218628Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Phase 1 · 54 location(s) · Incyte Corporation · NCT074416943'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET
Phase 2 · 8 location(s) · Xiamen Amoytop Biotech Co., Ltd. · NCT06552429Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Phase 2 · 33 location(s) · GlaxoSmithKline · NCT06517875A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Phase 1 · 26 location(s) · Incyte Corporation · NCT07008118A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Mye
Phase 1 · 29 location(s) · Incyte Corporation · NCT05936359Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CA
NA · 10 location(s) · University Hospital, Angers · NCT04942080Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Ne
Phase 2 · 1 location(s) · University of Washington · NCT04282187Asian Myeloproliferative Neoplasm (MPN) Registry
Phase N/A · 1 location(s) · The University of Hong Kong · NCT05882773Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Phase 1 · 7 location(s) · Novartis Pharmaceuticals · NCT07340138Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythem
Phase N/A · 6 location(s) · University Hospital, Angers · NCT05440838
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.